Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions

Executive Summary

FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago

You may also be interested in...



Consolidated CDER/CBER INDs renumbered

The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...

Consolidated CDER/CBER INDs renumbered

The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...

FDA Oncology Drug Reviews Headed By Justice Under Revised Structure

Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs

Related Content

UsernamePublicRestriction

Register

PS042451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel